Lonza Withdraws Majority of Claims in Patent Lawsuit Against Northwest Bioth...(those projectedin any forward-looking st...)

Date:12/20/2007

those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as uncertainties concerning the progress and ultimate outcome of the litigation involving Lonza Group AG. Additional information on these and other factors, which could affect the company's results, is included in its Securities and Exchange Commission ("SEC") filings. Finally, there may be other factors not mentioned above or included in the company's SEC filings that may cause actual results to differ materially those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.

'/>"/>

SOURCE Northwest Biotherapeutics, Inc. Copyright©2007 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related biology technology :

1. Martek to Obtain Permanent Injunction Against Lonza in U.S. Patent Infringement Suit; Jury Verdict on Infringement of Two of Three Patents Upheld by Judge
2. National Surgical Hospitals Acquires Majority Share of Houston-Area Surgery Center
3. Zimmer Holdings Announces Support for Elimination of Super-Majority Voting Requirements
4. Healthcare Announced That an Overwhelming Majority of its Shareholders Approved the NexGen Biofuels Transaction
5. DuPont Congratulates Growers Planting Pioneer(R) Brand Sorghum Hybrids in Winning Majority of National Categories in Yield Contest
6. Former Banc of America Securities Analyst David Maris Comments on Decision by Biovail to Drop Its Claims Against Him; Denies That He is Cooperating With Biovail
7. European Patent Office Upholds Martek European DHA Food Patent; Scope of Original Claims Narrowed
8. Dynavax Issued Landmark Patent Covering Second-Generation TLR9 Agonists
9. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
10. Pressure BioSciences, Inc. Issued First Patent in Canada
11. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent